Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension
Completed
GlaxoSmithKline
Phase 4
2005-10-01
The purpose of OM5/LOV111859 was to evaluate efficacy and safety of Omacor (omega-3-acid
ethyl esters) as add-on therapy to Antara (fenofibrate) and diet for the treatment of
patients with very high triglycerides.
The purpose of both OM5X/LOV111860 was to assess the continued efficacy and safety of
adjunctive Lovaza (omega-3-acid ethyl esters) therapy in hypertriglyceridemic subjects
treated with fenofibrate in lowering serum triglyceride (TG) levels.
Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Completed
GlaxoSmithKline
Phase 3
2005-11-01
The purpose of OM6 is to evaluate efficacy and safety of Lovaza (omega-3-acid ethyl esters)
[formerly known as Omacor] combined with simvastatin for lowering non-high-density
lipoprotein cholesterol (non-HDL-C) in subjects with persistent high triglycerides despite
statin therapy.
Additionally, a two-year extension trial (LOV111818/OM6X) is posted on NCT00903409.
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
Completed
GlaxoSmithKline
Phase 4
2006-10-01
The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in
HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will
evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and
inflammation.
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
Completed
National Center for Complementary and Integrative Health (NCCIH)
Phase 4
2006-10-01
The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in
HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will
evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and
inflammation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
